Recombinant adeno-associated virus for muscle directed gene therapy.
Although gene transfer with adeno-associated virus (AAV) vectors has typically been low, transduction can be enhanced in the presence of adenovirus gene products through the formation of double stranded, non-integrated AAV genomes. We describe the unexpected finding of high level and stable transgene expression in mice following intramuscular injection of purified recombinant AAV (rAAV). The rAAV genome is efficiently incorporated into nuclei of differentiated muscle fibers where it persists as head-to-tail concatamers. Fluorescent in situ hybridization of muscle tissue suggests single integration sites. Neutralizing antibody against AAV capsid proteins does not prevent readministration of vector. Remarkably, no humoral or cellular immune responses are elicited to the neoantigenic transgene product E. coli beta-galactosidase. The favorable biology of rAAV in muscle-directed gene therapy described in this study expands the potential of this vector for the treatment of inherited and acquired diseases.
Fisher
K J
KJ
Institute for Human Gene Therapy, University of Pennsylvania Health System, Philadelphia 19104, USA.
Jooss
K
K
Alston
J
J
Yang
Y
Y
Haecker
S E
SE
High
K
K
Pathak
R
R
Raper
S E
SE
Wilson
J M
JM
D000818:Animals; D004274:DNA, Recombinant / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D000229:Dependovirus / Q000235:genetics*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D051379:Mice; D008822:Mice, Transgenic; D018482:Muscle, Skeletal / Q000821:virology*
D004274:DNA, Recombinant; D004279:DNA, Viral